Loading the records…
Loading the records…
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, MANHARD KIMBERLY, holds the title of Director at Inhibrx Biosciences, Inc..
On 2026-09-11, the insider transacted 1,500 shares.The shares were transacted at a weighted average price of $109.03 per share, resulting in a total market-relevant value of $164K.
MANHARD KIMBERLY (Director) sold $164K of $INBX
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.